Document:

EX-4.1

 Exhibit 4.1 
  

 
 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PO PAR VALUE $0.0001 MR ADD ADD
ADD ADD 4 3 2 1 A BOX DESIGNATION SAMPLE Certificate Shares 43004, * * 000000 ****************** (IF Number * * * 000000 ***************** ANY) ZQ00000000 **** 000000 **************** Providence, PREVAIL THERAPEUTICS INC. ***** 000000
*************** RI ****** 000000 ************** INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE ** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample
**** Mr. Alexander David Sample SEE REVERSE FOR CERTAIN DEFINITIONS 02940 **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample ****
Mr. Alexander David - THIS CERTIFIES THAT Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample ****
Mr. MR. Alexander David SAMPLE Sample **** Mr. Alexander David &Sample MRS. **** Mr. Alexander SAMPLE David Sample **** Mr. Alexander & David    Sample **** Mr. 3004 Alexander David
Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr Alexander David Sample **** Mr. Alexander David Sample **** CUSIP XXXXXX XX X Mr. Alexander David Sample **** Mr. Alexander David Sample ****
Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David
Sample **** Mr. Alexander David Sample **** Mr. Alexander MR. David Sample SAMPLE **** Mr. Alexander David Sample **** &Mr. Alexander MRS. David Sample SAMPLE **** Mr. Alexander David Sample **** Mr. Alexander David
Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample ****
Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David
Sample **** Mr. Sample **** Mr. Sample is the owner of **000000**Shares FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Prevail Therapeutics Inc. (hereinafter called the “Company”),
transferable on the books of the Company in Total DTC person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and Holder the shares represented hereby, are issued and shall be held subject to all
of the provisions of the Certificate of Number Certificateof Insurance ID Incorporation, as amended, and the By-Laws, as amended, of the Company (copies of which are on file with the Value Company and with the
Transfer Agent), to all of which each holder, by acceptance hereof, assents. This Transaction Shares CUSIP/IDENTIFIER Certificate is not valid unless countersigned and registered by the Transfer Agent and Registrar. Numbers 1234567890/1234567890
1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 Witness the facsimile seal of the Company and the facsimile signatures of its duly authorized officers. DATED DD-MMM-YYYY ERAPE FACSIMILE SIGNATURE TO COME H U COUNTERSIGNED AND REGISTERED: T T L POR I I R A COMPUTERSHARE TRUST COMPANY, N.A.
12345678901234512345678    CO TE C Num/No A S V TRANSFERAGENT AND REGISTRAR, Denom. President E I R N C 666 555 444 333 222 111 P . XXXXXX July 6, 2017 Total. DEL RE FACSIMILE SIGNATURE TO COME AWA 7 00.1,000,000 XX 123456
XXXXXXXXXX X By Secretary AUTHORIZED SIGNATURE    . 

 

 
 PREVAIL THERAPEUTICS INC. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS,
DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS,
PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO
DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE, OR HIS LEGAL
REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE. The following abbreviations,
when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM - as tenants in common UNIF GIFT MIN ACT -Custodian (Cust) (Minor) TEN ENT
- as tenants by the entireties under Uniform Gifts to Minors Act (State) JT TEN    - as joint tenants with right of survivorship UNIF TRF MIN ACT    -Custodian (until age) and not as tenants in common
(Custunder Uniform Transfers to Minors Act (Minor) (State) Additional abbreviations may also be used though not in the above list. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE For value received, hereby sell, assign and
transfer unto (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) Shares of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said stock
on the books of the within-named Company with full power of substitution in the premises. Dated: 20 Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers,
Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15. Signature: Signature: Notice: The signature to this
assignment must correspond with the name as written upon the face of the certificate, in every particular, without alteration or enlargement, or any change whatever. The IRS requires that the named transfer agent (“we”) report the cost
basis of certain shares or units acquired after January 1, 2011. If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or units using a specific cost basis calculation method, then we have
processed as you requested. If you did not specify a cost basis calculation method, then we have defaulted to the first in, first out (FIFO) method. Please consult your tax advisor if you need additional information about cost basis. If you do not
keep in contact with the issuer or do not have any activity in your account for the time period specified by state law, your property may become subject to state unclaimed property laws and transferred to the appropriate state.EX-4.2

 Exhibit 4.2 

Execution Version 
 PREVAIL
THERAPEUTICS INC. 
 AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

DATED AS OF MARCH 19, 2019 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
			
	 1.
	  	Definitions	  	 	1	 
			
	 2.
	  	Registration Rights	  	 	5	 
		  	2.1	  	Demand Registration	  	 	5	 
		  	2.2	  	Company Registration	  	 	7	 
		  	2.3	  	Underwriting Requirements	  	 	7	 
		  	2.4	  	Obligations of the Company	  	 	8	 
		  	2.5	  	Furnish Information	  	 	10	 
		  	2.6	  	Expenses of Registration	  	 	10	 
		  	2.7	  	Delay of Registration	  	 	10	 
		  	2.8	  	Indemnification	  	 	10	 
		  	2.9	  	Reports Under Exchange Act	  	 	13	 
		  	2.10	  	Limitations on Subsequent Registration Rights	  	 	13	 
		  	2.11	  	“Market Stand-off” Agreement	  	 	13	 
		  	2.12	  	Restrictions on Transfer	  	 	14	 
		  	2.13	  	Termination of Registration Rights	  	 	16	 
			
	 3.
	  	Information and Observer Rights	  	 	16	 
		  	3.1	  	Delivery of Financial Statements	  	 	16	 
		  	3.2	  	Inspection	  	 	17	 
		  	3.3	  	Observer Rights	  	 	18	 
		  	3.4	  	Termination of Information and Observer Rights	  	 	19	 
		  	3.5	  	Confidentiality	  	 	19	 
			
	 4.
	  	Rights to Future Stock Issuances	  	 	20	 
		  	4.1	  	Right of First Offer	  	 	20	 
		  	4.2	  	Termination	  	 	21	 
			
	 5.
	  	Additional Covenants	  	 	21	 
		  	5.1	  	Insurance	  	 	21	 
		  	5.2	  	Employee Agreements	  	 	21	 
		  	5.3	  	Employee Stock	  	 	21	 
		  	5.4	  	Board Matters	  	 	22	 
		  	5.5	  	Successor Indemnification	  	 	22	 
		  	5.6	  	Right to Conduct Activities	  	 	22	 
		  	5.7	  	CFIUS	  	 	23	 
		  	5.8	  	Termination of Covenants	  	 	23	 
			
	 6.
	  	Miscellaneous	  	 	23	 
		  	6.1	  	Successors and Assigns	  	 	23	 
		  	6.2	  	Governing Law	  	 	24	 
		  	6.3	  	Counterparts	  	 	24	 
		  	6.4	  	Titles and Subtitles	  	 	24	 

  
 i 

									
		  	6.5	  	Notices	  	 	24	 
		  	6.6	  	Amendments and Waivers	  	 	24	 
		  	6.7	  	Severability	  	 	25	 
		  	6.8	  	Aggregation of Stock	  	 	25	 
		  	6.9	  	Additional Investors	  	 	26	 
		  	6.10	  	Entire Agreement	  	 	26	 
		  	6.11	  	Dispute Resolution	  	 	26	 
		  	6.12	  	Delays or Omissions	  	 	27	 
		  	6.13	  	Acknowledgment	  	 	27	 

  

					
	Schedule A	  	—	  	Schedule of Investors

  
 ii 

 AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 19th day of March, 2019, by
and among Prevail Therapeutics Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and any
Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof. 

RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Series A Preferred Stock, Series Seed
Preferred Stock, and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to an Amended and Restated Investors’ Rights Agreement dated as
of March 7, 2018, by and among the Company and the other parties thereto (the “Prior Agreement”), in connection with the purchase of shares of such Series A Preferred Stock; 

WHEREAS, the Existing Investors are Holders of a majority of the Registrable Securities of the Company (as defined in the Prior
Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; 

WHEREAS, certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement dated as of the date hereof
between the Company and certain of the Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by such
Investors, Existing Investors holding a majority of the Registrable Securities, and the Company. 
 NOW, THEREFORE, in consideration
of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors, including the Existing Investors, each hereby agree to amend and restate the Prior
Agreement in its entirety as set forth herein, and the parties hereto further agree as follows: 
 1. Definitions. For
purposes of this Agreement: 
 1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly
or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, member, officer or director of such Person or any venture capital fund or registered
investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company with, such Person. 

1.2 “Common Stock” means shares of the Company’s common stock, par value $0.0001 per share. 

 1.3 “Company Programs” means any of (i) gene therapy mediated
expression of GBA1, the gene encoding glucocerebrosidase (GCase), (ii) gene therapy mediated expression of Progranulin (GRN) and/or (iii) gene therapy mediated expression of knockdown alpha-synuclein. 

1.4 “Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited liability
company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the business of developing a directly competitive program or product utilizing the same mechanism of action as the Company Programs, but shall
not include (i) Citadel Multi-Strategy Equities Master Fund Ltd. (“Surveyor”) and its Affiliates, (ii) OrbiMed Private Investments VI, LP (“OrbiMed”), (iii) RA Capital Healthcare Fund, L.P. (“RA
Capital”), (iv) Pontifax (Israel) V Limited Partnership or its Affiliates, (v) any Investor that, together with its Affiliates, holds less than twenty percent (20%) of the outstanding equity of any Competitor or (vi) any Investor
solely because it has, or any of its Affiliates have, a right to designate members of the Board of Directors (or observers) of any Competitor, provided that such Investor shall not share Sensitive Information with any Competitor and shall in all
cases abide by the confidentiality restrictions set forth in Section 3.5. 
 1.5 “Damages” means any loss, damage,
claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises
out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any
amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation
by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities
law. 
 1.6 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for
(in each case, directly or indirectly), Common Stock, including options and warrants. 
 1.7 “Exchange Act” means
the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.8 “Excluded
Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145
transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; (iv) a registration in
which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered; or (v) the IPO. 

  
 2 

 1.9 “Form S-1” means such
form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.10 “Form S-3” means such form under the Securities Act as in effect on the
date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.11 “GAAP” means generally accepted accounting principles in the United States. 

1.12 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.13 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.14 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.15 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.16 “Key Employee” means any executive-level employee (including, division director and vice president-level
positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.17 “Major Investor” means any Investor and any Person to whom any of the rights of such Person are assigned pursuant to
Section 6.1 that, individually or together with such Investor’s Affiliates, (i) holds at least 1,000,000 shares of Common Stock, including Common Stock issued or issuable upon conversion of Preferred Stock (as defined below) (as
adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof), (ii) holds at least 350,000 shares of Series A Preferred Stock (as adjusted for any stock split, stock
dividend, combination, or other recapitalization or reclassification effected after the date hereof), (iii) Blackwell Partners LLC – Series A for so long as such Investor continues to hold at least 150,000 shares of Registrable Securities (as
adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof), or (iv) purchased at least 244,324 shares of Series B Preferred Stock pursuant to the Purchase Agreement.

 1.18 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as
well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

  
 3 

 1.19 “Person” means any individual, corporation, partnership, trust,
limited liability company, association or other entity. 
 1.20 “Preferred Directors” means the Series Seed Directors and
Series A Directors, collectively. 
 1.21 “Preferred Stock” means shares of the Company’s Series Seed Preferred
Stock, Series A Preferred Stock, and Series B Preferred Stock. 
 1.22 “Registrable Securities” means (i) the Common
Stock issuable or issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other
securities of the Company, held by the Investors as of the date hereof or acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any
warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however,
any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for
which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 
 1.23 “Registrable
Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly)
pursuant to then exercisable and/or convertible securities that are Registrable Securities. 
 1.24 “Restated Certificate”
means the Company’s Second Amended and Restated Certificate of Incorporation, as further amended from time to time. 
 1.25
“Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 

1.26 “SEC” means the Securities and Exchange Commission. 

1.27 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.28 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.29 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.30 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

  
 4 

 1.31 “Sensitive Information” means the confidential information from the
Company Programs. 
 1.32 “Series A Director” means any director of the Company that the holders of record
of the Series A Preferred Stock are entitled to elect pursuant to the Restated Certificate. 
 1.33 “Series A Preferred
Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001 per share. 
 1.34 “Series B
Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001 per share. 
 1.35 “Series
Seed Director” means any director of the Company that the holders of record of the Series Seed Preferred Stock are entitled to elect pursuant to the Restated Certificate. 

1.36 “Series Seed Preferred Stock” means shares of the Company’s Series Seed Preferred Stock, par value $0.0001 per
share. 
 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the
date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that
the Company file a Form S-1 registration statement with respect to Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least
$15 million (provided that in the case of the IPO such offering must also meet the requirements of a Qualified Public Offering, as such term is defined in the Restated Certificate) then the Company shall (x) within ten
(10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after
the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be
registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is
given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 
 (b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty percent (20%) of
the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering
price, net of Selling Expenses, of at least $2.5 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as
soon as practicable, and in any 

  
 5 

 
event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the
Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is
given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 
 (c) Notwithstanding the foregoing
obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board
of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain
effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the
Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with
respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided,
however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other
stockholder during such ninety (90) day period other than an Excluded Registration. 
 (d) The Company shall not be obligated to
effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that
is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become
effective; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i)
during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that
the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the
twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement
has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to
Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

  
 6 

 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the
provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by
it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration
shall be borne by the Company in accordance with Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the
Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if
the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that
otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as
nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities
held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company
or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 
 (b) In
connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such
underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of
the offering by the Company. If the total number of securities, 

  
 7 

 
including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their
reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the
Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the
Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as
shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one
hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first
entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in
which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection
2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and
Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with
respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c) For purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the
underwriter’s cutback provisions in Subsection 2.3(a), fewer than the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included. 

2.4 Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities,
the Company shall, as expeditiously as reasonably possible:(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to
become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the
distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains,
at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to 60 days, if necessary,
to keep the registration statement effective until all such Registrable Securities are sold; 

  
 8 

 (b) prepare and file with the SEC such amendments and supplements to such registration
statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

  
 9 

 (j) after such registration statement becomes effective, notify each selling Holder of any
request by the SEC that the Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall ensure
that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may
implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish
Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall
furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable
Securities. 
 2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations,
filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees
and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to
pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which
case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their
right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the
condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay
any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this
Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 

  
 10 

 (a) To the extent permitted by law, the Company will indemnify and hold harmless each
selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if
any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal
or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained
in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each
selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of
the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending
any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of
any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by
way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by
such Holder. 
 (c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of
any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8,
give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to
which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without
conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party

  
 11 

 
would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to
the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially
prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection
2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either:
(i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent
jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such
case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the
aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party
in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of
the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case
(x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no
event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net
of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the
foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions
in the underwriting agreement shall control. 
 (f) Unless otherwise superseded by an underwriting agreement entered into in connection
with the underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this
Section 2, and otherwise shall survive the termination of this Agreement. 

  
 12 

 2.9 Reports Under Exchange Act. With a view to making available to the Holders the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information, as those
terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies) and (ii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form
S-3 (at any time after the Company so qualifies to use such form). 
 2.10 Limitations on
Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any
holder or prospective holder of any securities of the Company that (i) would allow such holder or prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective
holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or
prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance
with Subsection 6.9. 
 2.11 “Market Stand-off”
Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company in its IPO of
shares of its Common Stock, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, or such other period as may be requested by the Company or an underwriter to
accommodate regulatory 

  
 13 

 
restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in
FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto) (such period, the “Restricted Period”), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase;
purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable
(directly or indirectly) for Common Stock (whether such shares or any such securities are then owned by the Holder or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any
of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions
of this Subsection 2.11 (a) shall apply only to the IPO, (b) shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit
of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value,
(c) shall be applicable to the Holders only if all officers, directors and stockholders individually, and together with their Affiliates, owning one percent (1%) or more of the Company’s outstanding Common Stock (after giving effect to
conversion into Common Stock of all outstanding Preferred Stock and the conversion, exercise or exchange of all outstanding Derivative Securities into or for Common Stock) are subject to the same restrictions and the Company obtains a similar
agreement from all such parties, (d) shall not apply to the transfer of any shares owned by a Holder in the Company to its Affiliates or any of the Holder’s stockholders, members, partners or other equity holders; provided that the
Affiliate, stockholder member, partner or other equity holder of the Holder agrees to be bound in writing by the restrictions set forth herein, and (e) shall not apply to shares of Common Stock acquired in the IPO or following the IPO; provided
that no filing under Section 16(a) of the Exchange Act shall be required or shall be voluntarily made during the Restricted Period by any Holder in connection with subsequent sales of Common Stock or other securities acquired in the IPO or
following the IPO. The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the
provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11
or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements,
based on the number of shares subject to such agreements. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 

  
 14 

 (b) Each certificate, instrument, or book entry representing (i) the Preferred Stock,
(ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event,
shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of
this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof
shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the
effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; (y) in any transaction in which such Holder
distributes Restricted Securities to an Affiliate of such Holder for no consideration or (z) in any internal transaction in which such Holder transfers Restricted Securities to an Affiliate of such Holder that is an entity and that is
ultimately controlled by the same parent 

  
 15 

 
company as the Holder (or is the ultimate parent company of the Holder); provided that, in the case of clauses (y) and (z), each transferee agrees in writing to be subject to the
terms of this Subsection 2.12. Notwithstanding the foregoing, the Company shall be obligated to reissue promptly unlegended certificates or book entries at the request of any Holder thereof if the Company has completed its IPO and the Holder
shall have obtained an opinion of counsel (which counsel may be counsel to the Company) to the effect that the securities proposed to be disposed of may lawfully be so disposed of without registration, qualification and legend, provided that the
second legend listed above shall be removed only at such time as the Holder of such certificate is no longer subject to any restrictions hereunder. Each certificate, instrument, or book entry representing the Restricted Securities transferred as
above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated
with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any
registration pursuant to Subsections 2.1 or 2.1(d) shall terminate upon the earliest to occur of: 
 (a) the closing of a
Deemed Liquidation Event, as such term is defined in the Restated Certificate; 
 (b) such time as Rule 144 or another similar exemption
under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(c) the fifth anniversary of the IPO. 

3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors
has not reasonably determined that such Major Investor is a Competitor: 
 (a) as soon as practicable, but in any event within one hundred
eighty (180) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as
of the end of such year; 
 (b) as soon as practicable, but in any event within forty-five
(45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’
equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain
all notes thereto that may be required in accordance with GAAP); 

  
 16 

 (c) as soon as practicable, but in any event within forty-five (45) days after the end
of each of the first three (3) quarters of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock
outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of
shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by
the chief financial officer or chief executive officer of the Company as being true, complete, and correct; 
 (d) as soon as practicable
before the end of each fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements,
and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 

(e) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major
Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a
trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company
and its counsel. 
 If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in
respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this
Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules
applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially
reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit each Major
Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account
and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall
not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement,
in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

  
 17 

 3.3 Observer Rights. 

(a) OrbiMed Observer. As long as OrbiMed owns not less than fifty percent (50%) of the shares of the Preferred Stock that it holds as
of the date hereof (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of OrbiMed (the “OrbiMed Observer”) to attend all meetings of its Board of Directors in a
nonvoting observer capacity and, in this respect, shall give such Observer copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors;
provided, however, that the Observer shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided. 

(b) EcoR1 Observer. As long as EcoR1 Capital Fund, L.P. (“EcoR1”) owns not less than fifty percent (50%) of the
shares of the Preferred Stock that it holds as of the date hereof (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of EcoR1 (the “EcoR1 Observer”) to attend
all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such Observer copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same
manner as provided to such directors; provided, however, that such Observer shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided. 

(c) RA Capital Observer. As long as RA Capital owns not less than fifty percent (50%) of the shares of the Preferred Stock that it
holds as of the date hereof (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of RA Capital (the “RA Capital Observer”) to attend all meetings of its Board of
Directors in a nonvoting observer capacity and, in this respect, shall give such Observer copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such
directors; provided, however, that such Observer shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided. 

(d) AbbVie Observer. If AbbVie Inc. (“AbbVie”) purchases Series B Preferred Stock at an Additional Closing (as
defined in the Purchase Agreement), as long as AbbVie owns not less than fifty percent (50%) of the shares of the Preferred Stock that it purchases pursuant to the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion
thereof), the Company shall invite a representative of AbbVie (the “AbbVie Observer”) to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such Observer copies of
all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such Observer shall agree to hold in confidence and
trust and to act in a fiduciary manner with respect to all information so provided. 

  
 18 

 (e) Surveyor Observer. As long as Surveyor owns not less than fifty percent (50%) of
the shares of the Preferred Stock that it holds as of the date hereof (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Surveyor (the “Surveyor Observer”, and
together with the OrbiMed Observer, the EcoR1 Observer, RA Capital Observer, and the AbbVie Observer each an “Observer”) to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall
give such Observer copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such Observer shall agree
to hold in confidence and trust all information so provided. 
 (f) Observer Reimbursement. The Company shall reimburse each
Observer for all reasonable out-of-pocket domestic travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of
the Board of Directors. 
 (g) Observer Restrictions. Notwithstanding anything to the contrary in this
Section 3.3, the Company shall have the right to withhold any information and to exclude an Observer from any meeting or portion thereof if, in the case of such Observer, such withholding or exclusion is appropriate (as
determined by the Board of Directors in its sole discretion) in order to (i) maintain the secrecy of the Company’s trade secrets or other similar highly confidential or proprietary information, (ii) fulfill the Company’s
obligations with respect to the confidential or proprietary information of third parties, (iii) preserve the attorney-client privilege between the Company and its counsel, or (iv) avoid a conflict of interest between the Company and such
Observer. In the case of an Observer who is deemed by the Board of Directors to be a direct or indirect Competitor or a representative of a Competitor, the Board of Directors may also withhold Sensitive Information and exclude (to the extent
necessary) such Observer from any meeting or portion thereof when Sensitive Information is being discussed. 
 3.4 Termination of
Information and Observer Rights. The covenants set forth in Subsection 3.1, Subsection 3.2, and Subsection 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO,
(ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate,
whichever event occurs first. 
 3.5 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not
disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file
a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been independently
developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third
party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in
connection with monitoring its investment in the Company; (ii) to any prospective 

  
 19 

 
purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.5; (iii) to any Affiliate,
partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the
confidentiality of such information; (iv) to the extent required in connection with any routine or periodic examination or similar process by any regulatory or self-regulatory body or authority not specifically directed at the Company or the
confidential information obtained from the Company pursuant to the terms of this Agreement, including, without limitation, quarterly or annual reports; or (v) as may otherwise be required by law, provided that the Investor promptly
notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 
 4. Rights
to Future Stock Issuances. 
 4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and
applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor. Each Investor shall be entitled to apportion the right of first offer hereby granted to it
in such proportions as it deems appropriate, among itself and its Affiliates. 
 (a) The Company shall give notice (the “Offer
Notice”) to each Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such
New Securities. 
 (b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Investor may elect
to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Investor (including all shares of Common
Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor) bears to the total Common Stock of the Company then outstanding
(assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Investor that elects to purchase or
acquire all the shares available to it (each, a “Fully Exercising Investor”) of the failure of any other Investor to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully
Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Investors were entitled to subscribe but that were not
subscribed for by the Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then
held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by
all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the
date of initial sale of New Securities pursuant to Subsection 4.1(c). 

  
 20 

 (c) If all New Securities referred to in the Offer Notice are not elected to be purchased
or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New
Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such
period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in
accordance with this Subsection 4.1. 
 (d) The right of first offer in this Subsection 4.1 shall not be applicable to
(i) Exempted Securities (as defined in the Restated Certificate) and (ii) shares of Common Stock issued in the IPO. 
 4.2
Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic
reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, whichever event occurs first. 

5. Additional Covenants. 

5.1 Insurance. The Company shall use its commercially reasonable efforts to maintain Directors and Officers liability insurance until
such time as the Board of Directors determines that such insurance should be discontinued. The key-person policy shall name the Company as loss payee, and neither policy shall be cancelable by the Company
without prior approval by the Board of Directors. 
 5.2 Employee Agreements. The Company will (i) cause each person now or
hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights
assignment agreement; and (ii) use commercially reasonable efforts to cause each future Key Employee to enter into a one (1) year noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of Directors.
In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of at
least a majority of the Preferred Directors. 
 5.3 Employee Stock. Unless otherwise approved by the Board of Directors,
including at least a majority of the Preferred Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be
required to execute restricted 

  
 21 

 
stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following
twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in Subsection 2.11. In addition, unless otherwise approved by the Board of Directors, including at least a majority of the Preferred Directors, the
Company shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

5.4 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall
meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel
expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. The Company shall cause to be established, as soon as practicable after such request, and will maintain, an audit
and compensation committee, each of which shall consist solely of non-management directors. Each Preferred Director shall be entitled in such person’s discretion to be a member of any Board committee.

 5.5 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other
Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the
Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Restated Certificate, or elsewhere, as the case
may be. 
 5.6 Right to Conduct Activities. The Company hereby agrees and acknowledges that certain of the Investors
(together with their Affiliates) are professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be
conducted). The Company further acknowledges and agrees that certain of the Investors or the Affiliates of such Investors (each, a “Strategic Investor”) may presently have, or may engage in the future in, internal development
programs, or may receive information from third parties that relates to, and may develop and commercialize products (independently or in cooperation with such third parties) that are similar to or that are directly or indirectly competitive with,
the Company’s development programs, products or services. The Company hereby agrees that, to the extent permitted under applicable law, such Investor shall not be liable to the Company for any claim arising out of, or based upon, (a) the
investment by such Investor in any entity competitive with the Company, or (b) actions taken by any partner, officer or other representative of such Investor to assist any such competitive company, whether or not such action was taken as a
member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company, provided further the Company agrees that the exercise by any Strategic Investor of any rights
under any of the financing agreements shall not in any way preclude or restrict such Strategic Investor from conducting any development program, commercializing any product or service or otherwise engaging in any enterprise, whether or not such
development program, product, service or 

  
 22 

 
enterprise competes with those of the Company; provided, however, that none of the foregoing shall not relieve (x) any of the Investors (together with their Affiliates) from liability
associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the
Company. Nothing herein or in any other financing agreement shall be construed to impose on any Strategic Investor any restriction, duty or obligation other than as expressly set forth herein or therein. 

5.7 CFIUS. To the extent that the Company in the future has actual knowledge that it is engaged in the design, fabrication,
development, testing, production or manufacture of any critical technologies within the meaning of Section 721 of the Defense Production Act of 1950, as amended, including all implementing regulations thereof, whether because of a new
categorization of technology by the U.S. government or otherwise, the Company shall provide notice to Omega Fund V, L.P. as soon as practicable. 

5.8 Termination of Covenants. The covenants set forth in this Section 5, except for Subsection
5.5 and Subsection 5.6, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, whichever event occurs first. 

6. Miscellaneous. 
 6.1
Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a
Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 50,000 shares of Registrable Securities (subject
to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of
the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the
terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an
Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with
those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single
attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure
to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

  
 23 

 6.2 Governing Law. This Agreement shall be governed by the internal law of the State
of Delaware. 
 6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during the recipient’s normal
business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or
(iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All
communications shall be sent to the respective parties at their addresses as set forth on Schedule A or Schedule B (as applicable) hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer,
in the case of the Company, or to such email address or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy (which shall not constitute notice) shall also
be sent to Cooley LLP, 500 Boylston Street, Boston, MA 02116, Attention: Marc Recht, Telephone: (617) 937-2316, Email: mrecht@cooley.com. 

6.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; provided that Subsections 3.1
and 3.2, this proviso, the proviso in the following sentence and any other section of this Agreement applicable to the Major Investors shall not be amended or waived to the detriment of any Major Investor or any of their respective Affiliates
without the consent of such Major Investor; provided that the Company may in its sole discretion waive an Investor’s compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after
notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); provided that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of
any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment,
termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Holders in the same
fashion if 

  
 24 

 
such waiver does so by its terms, notwithstanding the fact that certain Holders may nonetheless, by agreement with the Company, purchase securities in such transaction; provided, however, that
if, after giving effect to such waiver of Section 4 with respect to a particular transaction, a Major Investor purchases securities in such transaction or issuance (such Major Investor, a “Participating Investor”), such waiver
of the provisions of Section 4 shall be deemed to apply to each other Major Investor whose rights were waived or amended only if such other Major Investor has been provided the opportunity to purchase a proportional number of the New Securities
being offered by the Company in such transaction based on the pro rata purchase right of such other Major Investor set forth in Section 4, assuming a transaction size determined based upon the amount purchased by the Participating Investor that
invested the largest percentage in such transaction, subject to the notice and election periods set forth in Section 4). The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that
did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has
consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.
Further notwithstanding the foregoing: 
 (a) Clause (ii) of Section 1.4, the provisions of Subsection
3.3(a) and this Subsection 6.6(a) may not be amended, modified, terminated or waived without the written consent of OrbiMed; 

(b) The provisions of Subsection 3.3(b) and this Subsection 6.6(b) may not be amended, modified, terminated or waived without
the written consent of EcoR1; 
 (c) Clause (iii) of Section 1.4, the provisions of Subsection 3.3(c)
and this Subsection 6.6(c) may not be amended, modified, terminated or waived without the written consent of RA Capital; 
 (d)
Contingent upon AbbVie purchasing shares of Series B Preferred Stock pursuant to the Purchase Agreement within ten days of the date hereof, the provisions of Subsection 3.3(d) and this Subsection 6.6(d) may not be amended, modified,
terminated or waived without the written consent of AbbVie; 
 (e) Clause (i) of Section 1.4, clause
(iv) of Section 1.16, the provisions of Subsection 3.3(e) and this Subsection 6.6(e) may not be amended, modified, terminated or waived without the written consent of Surveyor. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. All shares of Registrable Securities
held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem
appropriate. 

  
 25 

 6.9 Additional Investors. Notwithstanding anything to the contrary contained herein,
if the Company issues additional shares of the Company’s Preferred Stock after the date hereof, any purchaser of such shares of any series of Preferred Stock may become a party to this Agreement by executing and delivering an additional
counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor,
so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Without limiting the generality of the preceding
sentence, the Prior Agreement shall be terminated in its entirety upon effectiveness of this Agreement. 
 6.11 Dispute Resolution.
The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of New York and to the jurisdiction of the United States District Court for the Southern District of New York for the purpose of any suit,
action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of New York or the United
States District Court for the Southern District of New York, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the
jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that
this Agreement or the subject matter hereof may not be enforced in or by such court. 
 WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO
A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE),
BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND
REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

  
 26 

 6.12 Delays or Omissions. No delay or omission to exercise any right, power, or
remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a
waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.13 Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital investing and therefore review
the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any
way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

[Remainder of Page Intentionally Left Blank] 

  
 27 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMPANY:
	
	PREVAIL THERAPEUTICS INC.
		
	By:	 	/s/ Asa Abeliovich
	Name:	 	Asa Abeliovich
	Title:	 	President
		
	Address:	 	430 East 29th St., Suite 940
		 	New York, NY 10016

  

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	CITADEL MULTI-STRATEGY EQUITIES MASTER
FUND LTD.
	
	By:    Citadel Advisors LLC, its portfolio manager
		
	By:	 	/s/ Noah Goldberg
	Name:	 	Noah Goldberg
	Title:	 	Authorized Signatory
		
	Address:	 	c/o Citadel Advisors LLC
		 	601 Lexington Avenue
		 	New York, NY 10022

  

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	ABBVIE INC.
	
	
		
	By:	 	/s/ William Chase
	Name:	 	William Chase
	Title:	 	EVP, Finance and Administration
		
	Address:	 	1 N. Waukegan Rd
		 	North Chicago, IL 60064

  

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	TANZAM, LLC
		
	By:	 	/s/ Sean Algeo
	Name:	 	Sean Algeo
	Title:	 	Controller
		
	Address:	 	689 Fifth Avenue, 12th Floor
		 	New York, NY 10022

  

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	MAXIM TRUST
		
	By:	 	Jackson Hole Trust Company, its Trustee

 
			
		
	By:	 	/s/ Julie Gilbert
	Name:	 	Julie Gilbert
	Title:	 	President – Jackston Hole Trust Company
		
	Address:	 	185 W. Broadway, Suite 101
		 	Jackson, WY 83001

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	JESRA VENTURES LLC
		
	By:	 	/s/ Francois Nader 
	Name:	 	Francois Nader
		
	Address:	 	6538 Collins Avenue, Suite 223
		 	Miami Beach, FL 33141

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	/s/ Christopher M. Wilfong
	CHRISTOPHER M. WILFONG
		
	Address:	 	663 Tremont Street, Unit 3
		 	Boston, MA 02118

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	ORBIMED PRIVATE INVESTMENTS VI, LP
		
	By:	 	OrbiMed Capital GP VI LLC,
		 	its General Partner
		
	By:	 	OrbiMed Advisors LLC,
		 	its Managing Member

 
			
		
	By:	 	/s/ Jonathan Silverstein 
	Name:	 	Jonathan Silverstein
	Title:	 	Member
		
	Address:	 	601 Lexington Avenue, 54th Floor
		 	New York, NY 10022
		 	c/o OrbiMed Advisors LLC

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	PONTIFAX LATE STAGE FUND L.P.
		
	By: 	 	/s/ Tomar Kariv / Ran Nussbaum 

 
			
	Name:	 	Tomar Kariv and Ran Nussbaum
	Title:	 	Managing Partners

 
			
	
	PONTIFAX (ISRAEL) V LIMITED PARTNERSHIP
		
	By: 	 	/s/ Tomar Kariv / Ran Nussbaum 

 
			
	Name:	 	Tomar Kariv and Ran Nussbaum
	Title:	 	Managing Partners

 
			
	
	PONTIFAX (CAYMAN) V L.P.
		
	By: 	 	/s/ Tomar Kariv / Ran Nussbaum 

 
			
	Name:	 	Tomar Kariv and Ran Nussbaum
	Title:	 	Managing Partners

 
			
	
	PONTIFAX (CHINA) V L.P.
		
	By: 	 	/s/ Tomar Kariv / Ran Nussbaum 

 
			
	Name:	 	Tomar Kariv and Ran Nussbaum
	Title:	 	Managing Partners

 
			
		
	 Address:
	 	14 Shenkar Street
		 	Herzelia, Israel
	
	With a copy (which shall not constitute notice) to:
	Horn & Co. Law Offices
	Amot Investments Tower
	2 Weizmann Street, 24th Floor
	Tel-Aviv, Israel 6423902
	Fax: +972-3-637 8201

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	EcoR1 CAPITAL FUND, L.P.
	By:	 	EcoR1 Capital, LLC, its General Partner

 
			
		
	By: 	 	/s/ Oleg Nodelman 

 
			
	Name:	 	Oleg Nodelman
	Title:	 	Managing Director

 
			
	
	ECOR1 CAPITAL FUND QUALIFIED, L.P.
	By: 	 	EcoR1 Capital, LLC, its General Partner
		
	By: 	 	/s/ Oleg Nodelman

 
			
	Name:	 	Oleg Nodelman
	Title:	 	Managing Director

 
			
		
	Address:	 	409 Illinois Street
		 	San Francisco, CA 94158

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	RA CAPITAL HEALTHCARE FUND, L.P.
		
	By:	 	RA Capital Management, LLC
	Its:	 	General Partner

 
			
	
		
	By: 	 	/s/ Peter Kolchinsky 

 
			
	Name:	 	Peter Kolchinsky
	Title:	 	Authorized Signatory
		
	Address:	 	RA Capital Management, LLC
		 	20 Park Plaza, Suite 1200
		 	Boston, MA 02116
		 	Attn: General Counsel

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	BLACKWELL PARTNERS LLC – SERIES A
		
	By: 	 	/s/ Adrienne C. Clough

 
			
	Name:	 	Adrienne C. Clough
	Title:	 	Investment Manager
		 	DUMAC, Inc., Authorized Agent

 
			
		
	By: 	 	/s/ Jannine M. Lall

 
			
	Name:	 	Jannine M. Lall
	Title:	 	Head of Finance & Controller
		 	DUMAC, Inc., Authorized Agent
		
	Address:	 	Blackwell Partners LLC – Series A
		 	280 S. Mangum Street, Suite 210
		 	Durham, NC 27701
		 	Attn: Jannine Lall

  
  

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	BIOTECHNOLOGY VALUE FUND, L.P.
		
	By:	 	/s/ Mark Lampert 

 
			
	Name:	 	Mark Lampert
	Title:	 	President BVF Inc., General Partner of BVF
	Partners L.P., itself General Partner of Biotechnology Value Fund, L.P.

  

			
	BIOTECHNOLOGY VALUE FUND II, LP
		
	By:	 	/s/ Mark Lampert 

 
			
	Name:	 	Mark Lampert
	Title:	 	President BVF Inc., General Partner of BVF
	Partners L.P., itself General Partner of Biotechnology Value Fund II, L.P.

  

			
	BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.
		
	By:	 	/s/ Mark Lampert 

 
			
	Name:	 	Mark Lampert
	Title:	 	President BVF Inc., General Partner of BVF
	Partners L.P., itself sole member of BVF Partners OS, Ltd., itself General Partner of Biotechnology Value Trading Fund OS, L.P.

  

			
	MSI BVF SPV L.L.C.
		
	By:	 	/s/ Mark Lampert 

 
			
	Name:	 	Mark Lampert
	Title:	 	President BVF Inc., General Partner of BVF
	Partners L.P., itself attorney-in-fact for MSI BVF SPV L.L.C.

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	OMEGA FUND V, L.P.
		
	By:	 	Omega Fund V GP, L.P.
		 	its General Partner
		
	By:	 	Omega Fund V GP Manager, Ltd.
		 	its General Partner
		
	By:	 	/s/ A-M. Paster
	Name:	 	A-M. Paster
	Title:	 	Director
		
	Address:	 	185 Dartmouth Street, Suite 502
		 	Boston, MA 02116
		 	c/o Omega Funds

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	BOXER CAPITAL, LLC
		
	By:	 	/s/ Aaron Davis 
	Name:	 	Aaron Davis
	Title:	 	CEO
	
	MVA INVESTORS, LLC
		
	By:	 	/s/ Aaron Davis 
	Name:	 	Aaron Davis
	Title:	 	CEO
		
	Address:	 	11682 El Camino Real, Suite 320
		 	San Diego, CA 92130

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	ADAGE CAPITAL PARTNERS, LP
		
	By:	 	Adage Capital Partners, GP, LLC
		 	its General Partner
	By:	 	Adage Capital Advisors, LLC
		 	its Managing Member
		
	By:	 	/s/ Dan Lehan
	Name:	 	Dan Lehan
	Title:	 	Chief Operating Officer
		
	Address:	 	200 Clarendon Street, 52nd Floor
		 	Boston, MA 02116

  

SIGNATURE PAGE TO PREVAIL THERAPEUTICS INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
	
	ALEXANDRIA VENTURE INVESTMENTS, LLC
	 a Delaware limited liability company

		
	By:	 	Alexandria Real Estate Equities, Inc., a Maryland corporation, its managing member

 
			
	
		
	By: 	 	/s/ Aaron Jacobson

 
			
	Name: 	 	Aaron Jacobson

 
			
	Title: 	 	SVP – Venture Capital

 
			
		
	Address:	 	385 E. Colorado Blvs. Suite 299
		 	Pasadena, CA 91101

 SIGNATURE
PAGE TO PREVAIL THERAPEUTICS INC. 
 AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	 INVESTORS:
  

		
	By: 	 	/s/ Divakar Gupta

 
			
	Name:	 	Divakar Gupta

 
			
		
	Address:	 	1114 Avenue of the Americas
		 	New York, NY 10036

 SIGNATURE PAGE TO PREVAIL
THERAPEUTICS INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTORS:
		
	By: 	 	/s/ Marc Recht

 
			
	Name:	 	Marc Recht

 
			
		
	Address:	 	500 Boylston Street
		 	Boston, MA 02116

 SIGNATURE PAGE TO PREVAIL
THERAPEUTICS INC. 
 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

Investors 
  

	
	 OrbiMed Private Investments VI, LP
  

c/o OrbiMed Advisors LLC 
601 Lexington Avenue, 54th Floor 
New York, NY 10022 
Attn: Jonathan Silverstein

	
	 Pontifax Late Stage Fund L.P.
  

14 Shenkar Street 
Herzelia, Israel 
Attn: Ran Nussbaum 
  

With a copy (which shall not constitute notice) to: 
Horn & Co. Law Offices, Amot Investments Tower 
2 Weizmann Street, 24th Floor 
Tel-Aviv 6423902, Israel 
Fax:+972-3-637 8201 

	
	 Pontifax (Israel) V Limited Partnership
  

14 Shenkar Street 
Herzelia, Israel 
Attn: Ran Nussbaum 
  

With a copy (which shall not constitute notice) to: 
Horn & Co. Law Offices, Amot Investments Tower 
2 Weizmann Street, 24th Floor 
Tel-Aviv 6423902, Israel 
Fax:+972-3-637 8201 

	
	 Pontifax (Cayman) V L.P.
  

14 Shenkar Street 
Herzelia, Israel 
Attn: Ran Nussbaum 
  

With a copy (which shall not constitute notice) to: 
Horn & Co. Law Offices, Amot Investments Tower 
2 Weizmann Street, 24th Floor 
Tel-Aviv 6423902, Israel 
Fax:+972-3-637 8201 

	
	 Pontifax (China) V L.P.
  

14 Shenkar Street 
Herzelia, Israel 
Attn: Ran Nussbaum 
  

With a copy (which shall not constitute notice) to: 
Horn & Co. Law Offices, Amot Investments Tower 
2 Weizmann Street, 24th Floor

Tel-Aviv 6423902, Israel 
Fax:+972-3-637 8201 

	
	 EcoR1 Capital Fund, L.P.
  

409 Illinois Street 
San Francisco, CA 94158 
Attn: Oleg Nodelman 

	
	 EcoR1 Capital Fund Qualified, L.P.
  

409 Illinois Street 
San Francisco, CA 94158 
Attn: Oleg Nodelman 

	
	 RA Capital Healthcare Fund, L.P.
  

RA Capital Management, LLC 
20 Park Plaza, Suite 1200 
Boston, MA 02116 
Attn: Peter Kolchinsky 

	
	 Blackwell Partners LLC 
  

280 S. Mangum Street, Suite 210 
Durham, NC 27701 
Attn: Jannine Lall 

	
	 Biotechnology Value Fund, L.P.
  

One Sansome Street, 30th Floor 
San Francisco, CA 94104 
Attn: Mark Lampert 

	
	 Biotechnology Value Fund II, L.P.
  

One Sansome Street, 30th Floor 
San Francisco, CA 94104 
Attn: Mark Lampert 

	
	 Biotechnology Value Trading Fund OS, L.P.
  

One Sansome Street, 30th Floor 
San Francisco, CA 94104 
Attn: Mark Lampert 

	
	 Investment 10, L.L.C.
  

One Sansome Street, 30th Floor 
San Francisco, CA 94104 
Attn: Mark Lampert 

	
	 MSI BVF SPV LLC
  

One Sansome Street, 30th Floor 
San Francisco, CA 94104 
Attn: Mark Lampert 

	
	 Omega Fund V, LP
  

c/o Omega Funds 
185 Dartmouth Street, Suite 502 
Boston, MA 02116 
Attn: A-M. Paster 

	
	 Boxer Capital, LLC
  

11682 El Camino Real, Suite 320 
San Diego, CA 92130 
Attn: Aaron Davis 

	
	 MVA Investors, LLC
  

11682 El Camino Real, Suite 320 
San Diego, CA 92130 
Attn: Aaron Davis 

	
	 Adage Capital Partners LP
  

200 Clarendon Street, 52nd Floor 
Boston, MA 02116 
Attn: Dan Lehan 

	
	 Alexandria Venture Investments, LLC
  

385 E. Colorado Blvd, Suite 299 
Pasadena, CA 91101 
Attn: Aaron Jacobson 

	
	 The Silverstein Foundation for Parkinson’s with GBA
  

[Address] 
[Address] 
Attn: 
Email:

	
	 REGENXBIO Inc.
  

[Address] 
[Address] 
Attn: 
Email:

	
	 Citadel Multi-Strategy Equities Master Fund Ltd.
  

c/o Citadel Advisors LLC 
601 Lexington Avenue 
New York, New York 
Attn: Noah Goldberg and Harry Greenbaum 

	
	 Maxim Trust
  

185 W Broadway, Suite 101 
Jackson, WY 83001 
Attn: Julie Gilbert 

	
	 Tanzam LLC
  

689 Fifth Avenue, 12th Floor 
New York, NY 10022 
Attn: Sean Algeo 

	
	 Christopher M. Wilfong
  

663 Tremont Street, Unit 3 
Boston, MA 02118 

	
	 Jesra Ventures LLC
  

6538 Collins Avenue, Suite 223 
Miami Beach, FL 33141 
Attn: Francois Nader 

	
	 Divakar Gupta
  

1114 Avenue of the Americas
 New York, NY 10036-7798

	
	 Marc Recht
  

500 Boylston Street
 Boston, MA 02116-3736

	
	 AbbVie, Inc.
  

1 North Waukegan Road North 
Chicago, IL 60064

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]